tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CATX Stock Latest News

Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
Company AnnouncementsPerspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
4d ago
8K
CATX
Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
PremiumRatings
Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
5d ago
CATX
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
PremiumCompany Announcements
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
6d ago
8K
CATX
Perspective Therapeutics provides business updates, strategic priorities
PremiumThe Fly
Perspective Therapeutics provides business updates, strategic priorities
6d ago
CATX
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data
PremiumCompany Announcements
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data
9d ago
8K
CATX
Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET
PremiumThe FlyPerspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET
9d ago
CATX
Perspective Therapeutics Updates Corporate Presentation on Advancements
Premium
Company Announcements
Perspective Therapeutics Updates Corporate Presentation on Advancements
2M ago
8K
CATX
Perspective Therapeutics assumed with a Buy at Truist
Premium
The Fly
Perspective Therapeutics assumed with a Buy at Truist
2M ago
CATX
Perspective Therapeutics price target lowered to $7 from $18 at UBS
PremiumThe Fly
Perspective Therapeutics price target lowered to $7 from $18 at UBS
2M ago
CATX
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
PremiumRatings
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
2M ago
CATX
Perspective Therapeutics price target lowered to $7 from $18 at UBS
PremiumThe Fly
Perspective Therapeutics price target lowered to $7 from $18 at UBS
2M ago
CATX
Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
PremiumThe Fly
Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
2M ago
CATX
TNGX
Perspective Therapeutics Reports Q3 2025 Results and Clinical Progress
PremiumCompany AnnouncementsPerspective Therapeutics Reports Q3 2025 Results and Clinical Progress
2M ago
CATX
Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience
Premium
Ratings
Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience
2M ago
CATX
Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
Premium
Ratings
Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
2M ago
CATX
Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential
PremiumRatings
Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential
2M ago
CATX
Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
PremiumThe Fly
Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
2M ago
SNY
CATX
Perspective Therapeutics Reports Promising Q3 2025 Results
PremiumCompany Announcements
Perspective Therapeutics Reports Promising Q3 2025 Results
2M ago
8K
CATX
Perspective Therapeutics reports Q3 EPS (35c), consensus (32c)
PremiumThe Fly
Perspective Therapeutics reports Q3 EPS (35c), consensus (32c)
2M ago
CATX
Perspective Therapeutics Updates Corporate Presentation on Pipeline
PremiumCompany AnnouncementsPerspective Therapeutics Updates Corporate Presentation on Pipeline
2M ago
8K
CATX
Perspective Therapeutics Updates Executive Employment Agreements
Premium
Company Announcements
Perspective Therapeutics Updates Executive Employment Agreements
3M ago
8K
CATX
Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study
Premium
Company Announcements
Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study
3M ago
CATX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >